Pancreatic Cancer Research

ResearcherUniversity of MiamiActive in the last 2 years

Ashok Kumar Saluja

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1139-9083; OpenAlex author ID A5031813021, A5108136094, A5135150113; NIH RePORTER profile ID 6485137. Sources: OpenAlex.

Their work

Papers
44 (first author 2, last author 22)
Trials
0
Grants
3
Labs led
2
Collaborators
64
Papers, trials and grants by year

2011: 2 papers · 2012: 2 papers · 2013: 4 papers · 2014: 3 papers · 2015: 2 papers · 2016: 6 papers, 1 grant · 2017: 4 papers · 2018: 4 papers · 2019: 3 papers · 2020: 2 papers · 2021: 5 papers, 1 grant · 2022: 3 papers, 1 grant · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 2 papers

Papers 44

  1. Metabolic dysfunction-associated steatotic liver disease accelerates pancreatic cancer progression and metastasis via the macrophage migration inhibitory facto… Co-author DOI 10.1038/s41392-025-02562-8↗
  2. SLC6A14-mediated carnitine transmembrane uptake from PPARγ+ cancer-associated fibroblasts promotes recurrence of pancreatic cancer. Co-author DOI 10.1136/gutjnl-2025-336116↗
  3. hnRNPLL regulates MYOF alternative splicing and correlates with early metastasis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2024.217436↗
  4. Hepatic Macrophage Migration Inhibitory Factor Promotes Pancreatic Cancer Liver Metastasis in NAFLD Co-author DOI 10.1101/2024.06.02.595997↗
  5. Minnelide synergizes with conventional chemotherapy by targeting both cancer and associated stroma components in pancreatic cancer. Last author DOI 10.1016/j.canlet.2022.215591↗
  6. Racial Disparity Between Whites and African Americans in Incidence and Outcome of Pancreatic Cancer: Have We Made a Difference? Co-author DOI 10.1053/j.gastro.2021.12.256↗
  7. Identification of novel early pancreatic cancer biomarkers KIF5B and SFRP2 from "first contact" interactions in the tumor microenvironment. Last author DOI 10.1186/s13046-022-02425-y↗
  8. An Immunocompetent Model of Pancreatic Cancer Resection and Recurrence. Co-author DOI 10.1007/s11605-020-04681-9↗
  9. Old Dog, New Tricks: Use of CA 19-9 for Early Diagnosis of Pancreatic Cancer Last author DOI 10.1053/j.gastro.2021.01.001↗
  10. Hsp70 modulates immune response in pancreatic cancer through dendritic cells. Co-author DOI 10.1080/2162402x.2021.1976952↗
  11. Hypoxia-Driven Oncometabolite L-2HG Maintains Stemness-Differentiation Balance and Facilitates Immune Evasion in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-20-2562↗
  12. Modulation of Early Neutrophil Granulation: The Circulating Tumor Cell-Extravesicular Connection in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/cancers13112727↗
  13. Learning From Gender Disparity: Role of Estrogen Receptor Activation in Coping With Pancreatic Cancer. Last author DOI 10.1016/j.jcmgh.2020.07.009↗
  14. Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy. Co-author DOI 10.1172/jci127515↗
  15. Targeting tumor intrinsic metabolic node in pancreatic cancer causes tumor regression,remodels extracellular matrix and sensitizes to anti-PD1 therapy Last author DOI 10.1016/j.pan.2019.05.430↗
  16. ER stress sensor, glucose regulatory protein 78 (GRP78) regulates redox status in pancreatic cancer thereby maintaining "stemness". Co-author DOI 10.1038/s41419-019-1408-5↗
  17. O-GlcNAc modification of Sox2 regulates self-renewal in pancreatic cancer by promoting its stability. Co-author DOI 10.7150/thno.32615↗
  18. GRP78-mediated antioxidant response and ABC transporter activity confers chemoresistance to pancreatic cancer cells. Co-author DOI 10.1002/1878-0261.12322↗
  19. Metastasis and chemoresistance in CD133 expressing pancreatic cancer cells are dependent on their lipid raft integrity. Co-author DOI 10.1016/j.canlet.2018.09.028↗
  20. A Theranostic Approach to Target Gastrin in Pancreatic Cancer. First author DOI 10.1016/j.jcmgh.2018.04.002↗
  21. Inactivation of Cancer-Associated-Fibroblasts Disrupts Oncogenic Signaling in Pancreatic Cancer Cells and Promotes Its Regression. Last author DOI 10.1158/0008-5472.can-17-2320↗
  22. Modulation of post-translational modifications in β-catenin and LRP6 inhibits Wnt signaling pathway in pancreatic cancer. Last author DOI 10.1016/j.canlet.2016.11.026↗
  23. Microenvironment in determining chemo-resistance in pancreatic cancer: Neighborhood matters. Co-author DOI 10.1016/j.pan.2016.12.010↗
  24. Inhibition of Sp1 prevents ER homeostasis and causes cell death by lysosomal membrane permeabilization in pancreatic cancer. Co-author DOI 10.1038/s41598-017-01696-2↗
  25. Inhibition of hypoxic response decreases stemness and reduces tumorigenic signaling due to impaired assembly of HIF1 transcription complex in pancreatic cancer. Co-author DOI 10.1038/s41598-017-08447-3↗
  26. Control of Apoptosis in Treatment and Biology of Pancreatic Cancer. Last author DOI 10.1002/jcb.25284↗
  27. A Novel Immunocompetent Mouse Model of Pancreatic Cancer with Robust Stroma: a Valuable Tool for Preclinical Evaluation of New Therapies. Co-author DOI 10.1007/s11605-015-2985-y↗
  28. Minnelide Overcomes Oxaliplatin Resistance by Downregulating the DNA Repair Pathway in Pancreatic Cancer. Last author DOI 10.1007/s11605-015-3000-3↗
  29. Inhibition of NF-kappa B pathway leads to deregulation of epithelial-mesenchymal transition and neural invasion in pancreatic cancer. Last author DOI 10.1038/labinvest.2016.109↗
  30. Evolution of novel therapeutic options for pancreatic cancer. Co-author DOI 10.1097/mog.0000000000000298↗
  31. Impaired Synthesis of Stromal Components in Response to Minnelide Improves Vascular Function, Drug Delivery, and Survival in Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-15-1155↗
  32. Minnelide effectively eliminates CD133(+) side population in pancreatic cancer. Co-author DOI 10.1186/s12943-015-0470-6↗
  33. CD133 initiates tumors, induces epithelial-mesenchymal transition and increases metastasis in pancreatic cancer. Last author DOI 10.18632/oncotarget.3228↗
  34. Triptolide sensitizes pancreatic cancer cells to TRAIL-induced activation of the death receptor pathway. Last author DOI 10.1016/j.canlet.2014.03.016↗
  35. Triptolide activates unfolded protein response leading to chronic ER stress in pancreatic cancer cells. Last author DOI 10.1152/ajpgi.00466.2013↗
  36. CD133+ tumor initiating cells in a syngenic murine model of pancreatic cancer respond to Minnelide. Last author DOI 10.1158/1078-0432.ccr-13-2947↗
  37. Relevance of animal models of pancreatic cancer and pancreatitis to human disease. Co-author DOI 10.1053/j.gastro.2013.01.070↗
  38. Triptolide-induced cell death in pancreatic cancer is mediated by O-GlcNAc modification of transcription factor Sp1. Last author DOI 10.1074/jbc.m113.500983↗
  39. Triptolide induces the expression of miR-142-3p: a negative regulator of heat shock protein 70 and pancreatic cancer cell proliferation. Last author DOI 10.1158/1535-7163.mct-12-1231↗
  40. miR-204 mediated loss of Myeloid cell leukemia-1 results in pancreatic cancer cell death. Last author DOI 10.1186/1476-4598-12-105↗
  41. A preclinical evaluation of Minnelide as a therapeutic agent against pancreatic cancer. Last author DOI 10.1126/scitranslmed.3004334↗
  42. MUC1c regulates cell survival in pancreatic cancer by preventing lysosomal permeabilization. Last author DOI 10.1371/journal.pone.0043020↗
  43. Myricetin induces pancreatic cancer cell death via the induction of apoptosis and inhibition of the phosphatidylinositol 3-kinase (PI3K) signaling pathway. Last author DOI 10.1016/j.canlet.2011.05.002↗
  44. Molecular targeted approaches for treatment of pancreatic cancer. First author DOI 10.2174/138161211796957427↗

Grants 3

  1. Role of HSP70 in Pancreatic Diseases R01CA124723↗
  2. The Role of Microbiome Modulation in Morphine-Induced Exacerbation of Pancreatitis R01DK117576↗
  3. Triptolide Augments Death Receptor Mediated Apoptosis in Pancreatic Cancer R01CA170946↗

Closest collaborators

The 25 strongest of 64 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sulagna Banerjee · 31 shared papers, 2012–2021 · strength 2.38
  2. Vikas Dudeja · 31 shared papers, 2011–2022 · strength 2.20
  3. Vineet Kumar Gupta · 13 shared papers, 2017–2022 · strength 1.34
  4. Bhuwan Giri · 12 shared papers, 2016–2022 · strength 1.05
  5. Nikita Sharma · 11 shared papers, 2017–2022 · strength 1.02
  6. Shrey Modi · 8 shared papers, 2016–2022 · strength 0.88
  7. Selwyn Maurice Vickers · 15 shared papers, 2011–2022 · strength 0.88
  8. Sundaram Ramakrishnan · 4 shared papers, 1 shared grant, 2016–2022 · strength 0.86
  9. Patricia Dauer · 9 shared papers, 2016–2019 · strength 0.72
  10. Alice Nomura · 10 shared papers, 2014–2018 · strength 0.68
  11. Qian Yu · 3 shared papers, 2024–2026 · strength 0.59
  12. Ruining Gong · 3 shared papers, 2024–2026 · strength 0.59
  13. He Ren · 3 shared papers, 2024–2026 · strength 0.59
  14. Sabita Roy · 1 shared grant, 2021 · strength 0.56
  15. Kousik Kesh · 6 shared papers, 2018–2021 · strength 0.54
  16. Anthony R. Ferrantella · 5 shared papers, 2019–2022 · strength 0.53
  17. Shweta Lavania · 4 shared papers, 2021–2022 · strength 0.52
  18. Eli Gilboa · 1 shared grant, 2022 · strength 0.52
  19. Harrys K.C. Jacob · 4 shared papers, 2021–2022 · strength 0.47
  20. Jigang Wang · 2 shared papers, 2024–2025 · strength 0.40
  21. Ashley Nicole Middleton · 3 shared papers, 2021–2022 · strength 0.37
  22. Vrishketan Sethi · 3 shared papers, 2021–2022 · strength 0.37
  23. Rohit Chugh · 7 shared papers, 2012–2016 · strength 0.32
  24. Olivia McGinn · 5 shared papers, 2013–2017 · strength 0.30
  25. Somnath Pandey · 2 shared papers, 2022 · strength 0.28

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.